Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
VEGFD Antibody
Purified Mouse Monoclonal Antibody (Mab)
- SPECIFICATION
- CITATIONS: 1
- PROTOCOLS
- BACKGROUND
Application 
| WB, E |
|---|---|
| Primary Accession | O43915 |
| Reactivity | Human, Mouse |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | Mouse IgG1 |
| Clone/Animal Names | 28AT743.288.48 |
| Calculated MW | 40444 Da |
| Gene ID | 2277 |
|---|---|
| Other Names | Vascular endothelial growth factor D, VEGF-D, c-Fos-induced growth factor, FIGF, FIGF, VEGFD |
| Target/Specificity | This monoclonal antibody is generated from mice immunized with three KLH conjugated synthetic peptides corresponding to N-terminal, central, and C-terminal sequences of human VEGF4. |
| Dilution | WB~~1:4000 |
| Format | Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | VEGFD Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | VEGFD (HGNC:3708) |
|---|---|
| Synonyms | FIGF |
| Function | Growth factor active in angiogenesis, lymphangiogenesis and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR/FLK1) and VEGFR-3 (FLT4) receptors. |
| Cellular Location | Secreted. |
| Tissue Location | Highly expressed in lung, heart, small intestine and fetal lung, and at lower levels in skeletal muscle, colon, and pancreas |
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms which bind and activate VEGFR-2 and VEGFR-3 receptors. This protein is structurally and functionally similar to vascular endothelial growth factor C.
References
A genetic association study of maternal and fetal candidate genes that predispose to preterm prelabor rupture of membranes (PROM). Romero R, et al. Am J Obstet Gynecol, 2010 Jul 29. PMID 20673868.
Clinical significance of vascular endothelial growth factors C and D and chemokine receptor CCR7 in gastric cancer. Deguchi K, et al. Anticancer Res, 2010 Jun. PMID 20651394.
Identification of fetal and maternal single nucleotide polymorphisms in candidate genes that predispose to spontaneous preterm labor with intact membranes. Romero R, et al. Am J Obstet Gynecol, 2010 May. PMID 20452482.
New genetic associations detected in a host response study to hepatitis B vaccine. Davila S, et al. Genes Immun, 2010 Apr. PMID 20237496.
Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2. Becker J, et al. Clin Cancer Res, 2010 Mar 1. PMID 20179233.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
